JP2008531739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531739A5 JP2008531739A5 JP2008500016A JP2008500016A JP2008531739A5 JP 2008531739 A5 JP2008531739 A5 JP 2008531739A5 JP 2008500016 A JP2008500016 A JP 2008500016A JP 2008500016 A JP2008500016 A JP 2008500016A JP 2008531739 A5 JP2008531739 A5 JP 2008531739A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- composition
- cell
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 56
- 239000000203 mixture Substances 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 20
- 241000700562 Myxoma virus Species 0.000 claims 14
- 241000700605 Viruses Species 0.000 claims 10
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 10
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 10
- 229960002930 sirolimus Drugs 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 102000014150 Interferons Human genes 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 206010038389 Renal cancer Diseases 0.000 claims 8
- 230000005860 defense response to virus Effects 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- 201000010982 kidney cancer Diseases 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 230000002950 deficient Effects 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010004593 Bile duct cancer Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 206010023825 Laryngeal cancer Diseases 0.000 claims 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 201000002510 thyroid cancer Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65881605P | 2005-03-07 | 2005-03-07 | |
| PCT/CA2006/000315 WO2006094385A1 (en) | 2005-03-07 | 2006-03-06 | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012197457A Division JP5674210B2 (ja) | 2005-03-07 | 2012-09-07 | 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531739A JP2008531739A (ja) | 2008-08-14 |
| JP2008531739A5 true JP2008531739A5 (https=) | 2009-04-16 |
Family
ID=36952904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500016A Pending JP2008531739A (ja) | 2005-03-07 | 2006-03-06 | 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用 |
| JP2012197457A Expired - Fee Related JP5674210B2 (ja) | 2005-03-07 | 2012-09-07 | 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012197457A Expired - Fee Related JP5674210B2 (ja) | 2005-03-07 | 2012-09-07 | 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20090035276A1 (https=) |
| EP (2) | EP2388315B1 (https=) |
| JP (2) | JP2008531739A (https=) |
| KR (1) | KR101479093B1 (https=) |
| CN (2) | CN102357104B (https=) |
| AU (1) | AU2006222500B2 (https=) |
| CA (1) | CA2600675C (https=) |
| DK (1) | DK2388315T3 (https=) |
| IL (2) | IL185376A0 (https=) |
| MX (1) | MX2007010962A (https=) |
| NZ (2) | NZ577283A (https=) |
| RU (1) | RU2461630C2 (https=) |
| UA (1) | UA96412C2 (https=) |
| WO (1) | WO2006094385A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090035276A1 (en) | 2005-03-07 | 2009-02-05 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| WO2007143548A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
| JP5748656B2 (ja) * | 2008-05-22 | 2015-07-15 | ジェ イル ファーマシューティカル カンパニー リミテッド | 過剰増殖細胞の腫瘍抑制因子に基づいた腫瘍崩壊ウイルスに対する感受性を判定する方法 |
| US20120100109A1 (en) * | 2010-10-26 | 2012-04-26 | Xiaoliu Zhang | Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors |
| WO2012171007A2 (en) | 2011-06-09 | 2012-12-13 | University Of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
| RU2695136C1 (ru) * | 2018-06-19 | 2019-07-22 | Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) | Онколитический способ терапии рака молочной железы. |
| EP3833367A4 (en) | 2018-08-08 | 2022-05-11 | Arizona Board of Regents on behalf of Arizona State University | Method for improved poxvirus yields |
| CA3112788A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| JP2022546985A (ja) * | 2019-09-02 | 2022-11-10 | アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティー | 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物 |
| EP4041266A1 (en) * | 2019-10-10 | 2022-08-17 | Arizona Board of Regents on behalf of Arizona State University | Oncolytic virus comprising immunomodulatory transgenes and uses thereof |
| AU2020361622A1 (en) * | 2019-10-10 | 2022-04-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic viruses that express multi-specific immune cell engagers |
| WO2022139440A1 (ko) * | 2020-12-22 | 2022-06-30 | 바이로큐어 주식회사 | 신규한 재조합 믹소마바이러스 및 이의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| EP1003894A2 (en) | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentiviral vectors |
| US7041654B2 (en) * | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| CN101618049A (zh) | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| US6264940B1 (en) * | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| AU6175000A (en) * | 1999-07-12 | 2001-01-30 | Viron Therapeutics, Inc. | Novel myxoma genes for immune modulation |
| BR0015491A (pt) * | 1999-11-12 | 2002-10-15 | Oncolytics Biotech Inc | Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro |
| WO2001087324A1 (en) * | 2000-05-17 | 2001-11-22 | Viron Therapeutics, Inc. | Compositions and methods for promoting immunosuppression |
| MX368013B (es) * | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| JP4800924B2 (ja) * | 2003-03-07 | 2011-10-26 | ロバーツ リサーチ インスティテュート | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
| DE602004004520T2 (de) * | 2003-04-22 | 2007-11-08 | Wyeth | Antineoplastische zusammensetzungen |
| WO2005002607A2 (en) * | 2003-07-07 | 2005-01-13 | Oncolytics Biotech Inc. | Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
| US20070207149A1 (en) * | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| US20090035276A1 (en) | 2005-03-07 | 2009-02-05 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
-
2006
- 2006-03-06 US US11/908,076 patent/US20090035276A1/en not_active Abandoned
- 2006-03-06 EP EP11174887.7A patent/EP2388315B1/en not_active Expired - Lifetime
- 2006-03-06 KR KR1020077022872A patent/KR101479093B1/ko not_active Expired - Fee Related
- 2006-03-06 CA CA2600675A patent/CA2600675C/en not_active Expired - Fee Related
- 2006-03-06 UA UAA200710934A patent/UA96412C2/ru unknown
- 2006-03-06 AU AU2006222500A patent/AU2006222500B2/en not_active Ceased
- 2006-03-06 WO PCT/CA2006/000315 patent/WO2006094385A1/en not_active Ceased
- 2006-03-06 JP JP2008500016A patent/JP2008531739A/ja active Pending
- 2006-03-06 NZ NZ577283A patent/NZ577283A/en not_active IP Right Cessation
- 2006-03-06 NZ NZ560840A patent/NZ560840A/en unknown
- 2006-03-06 CN CN201110306752.7A patent/CN102357104B/zh not_active Expired - Fee Related
- 2006-03-06 CN CN2006800075336A patent/CN101137748B/zh not_active Expired - Fee Related
- 2006-03-06 EP EP06705269A patent/EP1863906A4/en not_active Withdrawn
- 2006-03-06 RU RU2007137008/10A patent/RU2461630C2/ru not_active IP Right Cessation
- 2006-03-06 DK DK11174887.7T patent/DK2388315T3/da active
- 2006-03-06 MX MX2007010962A patent/MX2007010962A/es active IP Right Grant
-
2007
- 2007-08-20 IL IL185376A patent/IL185376A0/en unknown
-
2010
- 2010-08-04 US US12/850,599 patent/US20110195050A1/en not_active Abandoned
- 2010-09-07 IL IL208070A patent/IL208070A/en not_active IP Right Cessation
-
2012
- 2012-09-07 JP JP2012197457A patent/JP5674210B2/ja not_active Expired - Fee Related
- 2012-11-16 US US13/679,096 patent/US20130171106A1/en not_active Abandoned
-
2013
- 2013-10-09 US US14/049,737 patent/US9987315B2/en not_active Expired - Lifetime
-
2018
- 2018-05-07 US US15/972,994 patent/US20180256656A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011157399A5 (https=) | ||
| Rodrigues et al. | Pathogenesis of cholangiocarcinoma | |
| JP2008531739A5 (https=) | ||
| JP2012517427A5 (https=) | ||
| JP2011500713A5 (https=) | ||
| JP2013527232A5 (https=) | ||
| JP2011144201A5 (https=) | ||
| CA2517147A1 (en) | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection | |
| Rani et al. | Acetamides: chemotherapeutic agents for inflammation-associated cancers | |
| JP2013518124A5 (https=) | ||
| WO2021218965A1 (zh) | 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用 | |
| RU2007137008A (ru) | Применение комбинации вируса миксомы и рапамицина для терапевтического лечения | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| CN109498629A (zh) | 一种小分子抑制剂用于结直肠癌化疗敏感性的应用 | |
| JP2011500650A5 (https=) | ||
| JP2020509035A5 (https=) | ||
| Singh et al. | Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer | |
| Song et al. | Benzamide‐Containing Histone Deacetylase Inhibitors With Anticancer Therapeutic Potential | |
| JP2010519274A5 (https=) | ||
| JP2007511492A5 (https=) | ||
| CN103096885A (zh) | 不饱和脂肪酸用于抑制病毒复制和/或感染的用途 | |
| Zhao et al. | A novel oral form of pentamidine (OCZ103) blocks TNF-mediated mouse liver injury from GalN/LPS: 1072 | |
| Phillips et al. | 506 Alisporivir-induced inhibition of cellular cyclophilins disrupts hepatitis B virus (Hbv) replication in vitro and is synergistic in combination with direct antiviral targeting HBV-DNA polymerase | |
| Godofsky et al. | PHASE I SINGLE-DOSE STUDY OF BAVITUXIMAB, A CHIMERIC ANTI-PHOSPHATIDYLSERINE MONOCLONAL ANTIBODY, IN SUBJECTS WITH CHRONIC HEPATITIS C: 127 | |
| ES2539160T3 (es) | Procedimiento de tratamiento de cáncer gástrico |